First patient treated in extended phase I trial of Antisoma's AS1411

07-Sep-2005
Cancer drug developer Antisoma announced that it has reopened a US phase I trial of its aptamer drug AS1411 following the presentation of promising data at this year's American Society of Clinical oncology meeting. The study is now enrolling patients with renal and non-small cell lung cancers. Signs of anti-cancer activity were seen in all of the three renal cancer patients included in the original trial, and Antisoma has recently been granted US orphan drug status for AS1411 in renal cancer.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances